Vaccine:
Covid-19 vaccine (CoronaVac)

Return to company overview

SinoVac Vaccine Summary Scorecard

A: Commitments and AccountabilityScoreC: International cooperationScore
A1 The company publishes a global access plan for its productC1 The company commits to C-TAP or MPP
A2 The company commits to comply with human rights standards in relation to product development and marketing C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator
C4 The company agrees to license its Covid-19 medical products to other companies
E: Equality, non-discrimination & equityScoreT: TransparencyScore
E1 The company makes the active ingredient available on reasonable ground. [Only for therapeutics]T1 The company publishes its R&D costs.
E2 The company commits to full technology transfer to other manufacturersT2 The company publishes its profit margin.
E3 The company commits to non-profit, ‘fair’, or differential pricingT3 The company publishes the average and/or marginal costs of production.
E4 The company equitably distributes supplies globally. [Only applies to vaccines]T4 The company publishes its production capacity.
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]T5 The company publishes the public subsidies it received during product development and/or testing.
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable].T6 The company publishes the text of licensing agreements.
T7 The company registers its clinical trials in public repositories.

SinoVac Vaccine Detailed Evaluation

Explore the results of PAF’s research into SinoVac’s behaviour. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading). 

A: Commitments and Accountability

Overall score:

A1 The company publishes a global access plan for its product 
  • No global access plan published.
  • Score: 
A2 The company commits to comply with human rights standards in relation to product development and marketing
  • No commitment to human rights
  • Score: 

C: International Cooperation

Overall score:

C1 The company commits to C-TAP or MPP 
  • No evidence of committing to a responsible licensing mechanism
  • Score: 
C2 The company commits to not enforcing the exclusive rights of Covid-19 related patents  
  • No commitment not to enforce patents.
  • Score: 
C3 The company supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator 
C4 The company agrees to license its Covid-19 medical products to other companies 
  • Yes, Butantan in Brazil (so far: clinical development collaboration but future agreements will include tech licensing and commercialization rights) and Pharmaniaga in Malaysia (fill and finish)
  • Score: 

E: Equality, non-discrimination & equity

Overall score:

E1 The company makes the active ingredient available on reasonable ground

[Only relevant for therapeutics]

E2 The company commits to full technology transfer to other manufacturers
  • Butantan: so far is a clinical development collaboration but future agreements will include tech licensing and commercialization rights; Pharmaniaga: ‘Local manufacturing’ agreement (fill and finish)
  • Plans to “select 10 countries for technology transfer as soon as possible”
  • Score: 
E3 The company commits to non-profit or ‘fair’ pricing

  • 5 USD per dose in Thailand and other South-East Asian countries but 38 USD in the Philippines and 14 USD in India, 17USD in Indonesia, around 30USD for China and Thailand

  • Diplomatic ties seem to determine price of vaccines between LMICs, not determined by ability to pay

  • Score:
E4 The company equitably distributes supplies globally. [Only applies to vaccines]
  • Sinovac has signed supply agreements for 993.221.000 doses outside of China. 993.221.000 doses – 500.000 doses for Mauritius – 200.000 doses for Singapore – 7.500.000 doses for Hong Kong = 980.521.000 doses for LMICs /993.221.000 x 100 = +/-98.72 of doses sold to LMICs (does not include doses for China itself, but since China is a middle-income country this does not make any difference for the result).
  • Score:  
E5 The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]
  • No information.
  • Score:  
E6 The company agrees to waive exclusive rights in regulatory test data [where applicable]  
  • No information.
  • Score:

T: Transparency

Overall score:

T1 The company publishes its R&D costs 
  • Financial reports only published up to 2018
  • Score: 
T2 The company publishes its profit margin 
  • No. See T1
  • Score:
T3 The company publishes the average and/or marginal costs of production
  • No
  • Score:
T4 The company publishes its production capacity
T5 The company publishes the public subsidies it received during product development and/or testing
T6 The company publishes the text of licensing agreements
  • No licensing agreement texts are published.
  • Score: 
T7 The company registers its clinical trials in public repositories
  • Yes
  • Score: